Trump signs order easing psychedelic drug restrictions for mental‑health research

President Donald J. Trump signed an executive order on April 17, 2026 that loosens federal restrictions on psychedelic drugs, including ibogaine, to speed mental‑health research. ^[1]

The move matters because the U.S. faces a mental‑health crisis, with more than 50 million adults reporting serious psychological distress. Accelerating research could expand treatment options for severe depression, post‑traumatic stress disorder and other conditions that have resisted conventional therapy. —

Psychedelic substances such as psilocybin, LSD and ibogaine have shown promise in early trials, but strict scheduling under the Controlled Substances Act has limited large‑scale studies. The new order directs the Drug Enforcement Administration to re‑classify certain compounds and requires the Food and Drug Administration to prioritize review of clinical trial applications. ^[2]

The order tasks the National Institute of Mental Health with coordinating a national research agenda, allocating $250 million over the next five years for multi‑center trials. It also calls for streamlined data‑sharing agreements between universities, private biotech firms and federal agencies. ^[3]

Mental‑health advocates said the policy shift could help patients with treatment‑resistant disorders who have few effective alternatives. "We have been waiting for federal leadership to remove unnecessary barriers," a spokesperson for the American Psychiatric Association said.

Industry analysts said a surge in investment for psychedelic‑focused startups is likely, noting they have raised $1.2 billion in venture capital since 2022. Faster approvals could shorten development timelines, potentially creating a new market segment worth billions of dollars.

Critics said the move bypasses the usual scientific review process, raising concerns about safety and ethical oversight.

Experts said that while the order removes administrative hurdles, rigorous randomized controlled trials remain essential to establish efficacy and monitor adverse effects. Past incidents of adverse reactions to ibogaine in unregulated settings underscore the need for strict clinical protocols.

**What this means** – The executive order could expedite the generation of high‑quality evidence on psychedelic therapies, potentially adding new tools to the mental‑health arsenal. However, the speed of policy change must be matched by careful scientific scrutiny to ensure treatments are both safe and effective before they reach patients.